Clinical Genomics and Experimental Therapeutics

临床基因组学和实验治疗学

• 批准号: 9155431
• 负责人: Falk Lohoff
• 金额: $ 301.04万
• 依托单位: NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9155431
• 关键词: Affect; Affective; Anxiety Disorders; Area; Biological Markers; Clinical; Clinical Research; DNA Sequence; Dopamine; Emotions; Epigenetic Process; Fright; Functional Imaging; Functional disorder; Genetic; Genomics; Genotype; Human; Individual Differences; Intervention; Methods; Molecular; Neurobiology; Neurons; Other Genetics; Pharmacogenetics; Pharmacological Treatment; Phase; Post-Traumatic Stress Disorders; Process; Proteomics; RNA Sequences; Regulation; Research; Risk; Signal Transduction; Subgroup; Therapeutic; Translating; Treatment outcome; Work; addiction; alcohol use disorder; base; dopamine transporter; emotion regulation; genetic approach; genome-wide; human population genetics; interest; neurobiological mechanism; next generation; novel therapeutics; pre-clinical; precision medicine; preclinical study; problem drinker; research study; transcriptome sequencing; treatment response

Section on Clinical Genomics and Experimental Therapeutics (SCGET) 1. Conducts pre-clinical studies and translational clinical studies with focus on genomics and epigenetics related to the pathophysiology and treatment of alcohol use disorders and addictions. 2. Pre-clinical work focuses on identifying molecular mechanisms involved in addictions, utilizing a wide array of methods including human population genetics, genome wide genotyping approaches, next-generation DNA and RNA sequencing, and epigenetic/proteomic profiling. 3. Findings are translated into human clinical studies using molecular biomarker, pharmacogenetic, epigenetic and functional imaging genetic approaches. 4. Clinical studies include early phase 1 / phase 2 proof-of-concept studies of experimental novel therapeutics guided by molecular biomarker profiling.

临床基因组学与实验治疗学部(SCGET) 1.开展以基因组学为重点的临床前研究和转化性临床研究 以及与酒精使用障碍的病理生理学和治疗相关的表观遗传学 上瘾。 2.临床前工作侧重于确定与成瘾有关的分子机制， 利用广泛的方法，包括人类群体遗传学，全基因组 基因分型方法、下一代DNA和RNA测序以及 表观遗传学/蛋白质组学。 3.使用分子生物标记物将发现转化为人类临床研究， 药物遗传学、表观遗传学和功能成像遗传学方法。 4.临床研究包括早期阶段1/阶段2实验性概念验证研究 分子生物标志物图谱指导的新疗法。